Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco January DIC 600x60px

News > All

Total search results: 16865 | Ordered by Source (ascending)
1 2 3 ... 167 168 169  next pagenext page

order ascendingorder descendingSource order ascendingorder descendingDate
10x Genomics Inc.. (12/10/18). "Press Release: 10x Genomics Acquires Spatial Transcriptomics". Pleasanton, CA. 2018-12-10
10x Genomics Inc.. (4/26/18). "Press Release: 10x Genomics Completes $50 Million Series D Financing and $75M Debt Facility". Pleasanton, CA. 2018-04-26
14M Genomics Ltd.. (12/16/14). "Press Release: 14M Genomics and Syncona Sign £12.5 Million Financing to Develop Cancer Genomic Diagnostics in Partnership with the Wellcome Trust Sanger Institute". 2014-12-16
14M Genomics Ltd.. (2/10/15). "Press Release: 14M Genomics and the Haematological Malignancy Research Network Collaborate on Clinical Genomic Profiling in Blood and Lymphatic Cancers". Cambridge. 2015-02-10
14M Genomics Ltd.. (3/10/15). "Press Release: 14M Genomics and the European Organisation for Research and Treatment of Cancer Collaborate on Genomic Profiling for Clinical Trials". Cambridge. 2015-03-10
14M Genomics Ltd.. (7/14/15). "Press Release: 14M Genomics Appoints Alan Schafer as Chief Executive Officer". Cambridge. 2015-07-14
1st Detect Corporation. (3/6/12). "Press Release: 1st Detect Awarded EU Patent for Chemical Detection Technology". Austin, TX. 2012-03-06
1st Detect Corporation. (9/25/12). "Press Release: 1st Detect MMS-1000 Launched in European Union with TransGlobal Distributors". Austin, TX. 2012-09-25
23andMe, Inc.. (1/28/09). "Press Release: 23andMe and mondoBIOTECH Partner to Advance Research of Rare Diseases". Davos. 2009-01-28
2B BlackBio S.L.. (10/25/11). "Press Release: BlackBio Gets more than 2 Million Euros after Capital Increase and Public Funding". 2011-10-25
2B BlackBio S.L.. (2/15/10). "Press Release: BlackBio, Making Personalized Medicine a Reality. Established in 2009 BlackBio Is a Biotechnology Spin-off Company Committed to Making Personalized Medicine an Affordable Reality". 2010-02-15
2B BlackBio S.L.. (2/27/12). "Press Release: The Spanish Biotechnological Companies, Biotools and 2B BlackBio, Reach an Agreement with the Mexican Pharmaceutics Silanes Laboratories". 2012-02-27
2cureX ApS. (10/21/09). "Press Release: 2cureX Announces Issuance of Patent On Its ChemoCellomics Technology". Copenhagen. 2009-10-21
2cureX ApS. (12/6/10). "Press Release: The Danish Council for Strategic Research Supports 2cureX and Its Academic Partners". Copenhagen. 2010-12-06
2cureX ApS. (6/8/10). "Press Release: 2cureX Announces Issuance of Final Patent Completing the Protection of the ChemoCellomics Technology". Copenhagen. 2010-06-08
3B Pharmaceuticals GmbH. (11/20/18). "Press Release: Ipsen and 3BP Announce First Patient Dosed in Phase I/II Study for First-in-class Radionuclide (IPN01087)". Paris. 2018-11-20
3P Biopharmaceuticals S.L.. (12/20/13). "Press Release: Dámaso Molero, a New Member of the Board of Directors of Asebio". 2013-12-20
3P Biopharmaceuticals S.L.. (4/14/14). "Press Release: 3P Biopharmaceuticals Invests 630,000€ in Increasing Its Capacity Development". 2014-04-14
3P Biopharmaceuticals S.L.. (4/23/15). "Press Release: 3P Biopharmaceuticals Produces a Cellular Drug for the First Clinical Trial of Acute Myocardial Infarction with Allogeneic Cardiac Stem Cells". 2015-04-23
3P Biopharmaceuticals S.L.. (5/5/15). "Press Release: 3P Biopharmaceuticals Acquires a Mass Spectrometer". 2015-05-05
3P Biopharmaceuticals S.L.. (7/10/13). "Press Release: 3P Biopharmaceuticals Will Participate in a Major European Project Aiming to Develop a Universal Influenza Virus Vaccine". 2013-07-10
4-Antibody AG. (1/29/13). "Press Release: 4-Antibody AG and the Ludwig Institute Expand Oncology Antibody R&D Program with Three New Targets". Basel & New York, NY. 2013-01-29
4-Antibody AG. (10/8/12). "Press Release: 4-Antibody AG Receives Additional Milestone Payments from Human Genome Sciences". Basel. 2012-10-08
4-Antibody AG. (3/16/10). "Press Release: 4-Antibody Announces Long-term Collaboration with Boehringer Ingelheim for Therapeutic Antibodies". Basel. 2010-03-16
4-Antibody AG. (8/16/11). "Press Release: 4-Antibody AG Forms Collaboration with Human Genome Sciences". Basel. 2011-08-16
4-Antibody AG. (9/11/09). "Press Release: Retrocyte Display Technology Patent Applications Published". Basel. 2009-09-11
4-Antibody AG. (9/19/11). "Press Release: 4-Antibody AG Meets Next Milestone in Boehringer Ingelheim Collaboration". Basel. 2011-09-19
4-Antibody AG. (9/21/09). "Press Release: 4-Antibody Received Notice of Allowance for U.S. Patent Application Describing the Hu-PAC Technology". Basel. 2009-09-21
4D Molecular Therapeutics. (4/30/18). "Press Release: 4DMT and Roche Expand Ophthalmology Partnership to Develop and Commercialize Multiple AAV Gene Therapy Products". Emeryville, CA. 2018-04-30
4D Pharma plc. (12/8/15). "Press Release: Placing to Raise £30 Million by the Issue of 3,797,469 New Ordinary Shares at 790p per Share". 2015-12-08
4D Pharma plc. (2/10/16). "Press Release: Acquisition [of Tucana Health Ltd.]". 2016-02-10
4DCell Fate Project. (2/13/12). "Press Release: Cell Fate in 4D. Bringing together European Excellence to Uncover the Mechanisms at Work that Determine Cell Fate". Barcelona. 2012-02-13
4P-Pharma. (9/1/16). "Press Release: Signature of a License Agreement with 4P-Pharma for the Development of an Anti-cancer Drug". Talence. 2016-09-01
4SC AG. (1/12/15). "Press Release: Prof. Dr. Helga Rübsamen-Schaeff and Joerg von Petrikowsky Join the Supervisory Board of 4SC AG". Planegg-Martinsried. 2015-01-12
4SC AG. (1/13/15). "Press Release: Beyond Research Initiative of 4SC Discovery and Crelux Reaches First Milestone in Drug Discovery Project for Helmholtz Zentrum München". Planegg-Martinsried & Munich. 2015-01-13
4SC AG. (1/19/12). "Press Release: 4SC’s Cancer Compound Resminostat Meets Primary Endpoint in Phase II Trial in Advanced Liver Cancer (HCC) ahead of Schedule". Planegg-Martinsried. 2012-01-19
4SC AG. (1/20/11). "Press Release: 4SC Announces First Patient Dosed in Phase I/II SHORE Study in KRAS-mutant Colorectal Cancer Patients with Resminostat". Planegg-Martinsried. 2011-01-20
4SC AG. (1/21/11). "Press Release: 4SC Presents Update on Phase II SHELTER Trial with Oral Pan-HDAC Resminostat at the 2011 Gastrointestinal Cancer Symposium". Planegg-Martinsried. 2011-01-21
4SC AG. (1/23/15). "Press Release: 4SC AG Plans Extraordinary General Meeting and Reduction of Share Capital". Planegg-Martinsried. 2015-01-23
4SC AG. (1/7/11). "Press Release: 4SC Announces First-in-Man Phase I Results for 4SC-203". Planegg-Martinsried. 2011-01-07
4SC AG. (1/8/13). "Press Release: 4SC Obtains Key Patent for Anti-cancer Compound Resminostat in Europe". Planegg-Martinsried. 2013-01-08
4SC AG. (10/1/12). "Press Release: 4SC Obtains Key Patent for Anti-cancer Compound Resminostat in China". Planegg-Martinsried. 2012-10-01
4SC AG. (10/10/17). "Press Release: Resminostat Demonstrates Potential to Significantly Alleviate Itching in CTCL Patients". Planegg-Martinsried. 2017-10-10
4SC AG. (10/21/16). "Press Release: Dr Daniel Vitt to Step Down as CDO/CSO and from the Management Board at the End of 2016". Planegg-Martinsried. 2016-10-21
4SC AG. (10/23/12). "Press Release: 4SC Discovery Receives Research Grant of EUR 600,000 for Development of Personalised Cancer Drugs". Planegg-Martinsried. 2012-10-23
4SC AG. (10/26/10). "Press Release: 4SC Announces Initial Phase II Data from the SAPHIRE Study with Resminostat at the 8th International Symposium on Hodgkin Lymphoma". Planegg-Martinsried. 2010-10-26
4SC AG. (10/26/17). "Press Release: 4SC Provides Q3 and 9M 2017 Update". Planegg-Martinsried. 2017-10-26
4SC AG. (11/11/10). "Press Release: 4SC Reports First Nine Months Financial Results 2010". Planegg-Martinsried. 2010-11-11
4SC AG. (11/16/10). "Press Release: 4SC to Highlight the Potential of Its Oncology Compounds at the 22nd EORTC-NCI-AACR Symposium »on Molecular Targets and Cancer Therapeutics«". Planegg-Martinsried. 2010-11-16
4SC AG. (11/4/10). "Press Release: 4SC’s Vidofludimus Meets Primary Endpoint with Excellent Response Rate in IBD Trial. Vidofludimus Generates a Response Rate of 88.5% for the Treatment of Patients with Crohn’s Disease and Ulcerative Colitis". Planegg-Ma 2010-11-04
4SC AG. (11/4/13). "Press Release: AiCuris, 4SC Discovery and Crelux Announce Drug Discovery Collaboration". Planegg-Martinsried & Wuppertal. 2013-11-04
4SC AG. (11/6/14). "Press Release: 4SC Announces Financial Results for the First Nine Months and the Third Quarter of 2014". Planegg-Martinsried. 2014-11-06
4SC AG. (11/7/11). "Press Release: 4SC Presents Encouraging Final Results of Vidofludimus Phase IIb COMPONENT Study in Rheumatoid Arthritis at ACR Meeting in Chicago". Planegg-Martinsried. 2011-11-07
4SC AG. (11/7/13). "Press Release: 4SC Announces Improved Financial Results for the Third Quarter and First Nine Months of 2013". Planegg-Martinsried. 2013-11-07
4SC AG. (11/8/11). "Press Release: 4SC Announces Financial Results for the Third Quarter and First Nine Months of 2011". Planegg-Martinsried. 2011-11-08
4SC AG. (11/8/12). "Press Release: 4SC’s Successful Development Continues in Third Quarter of 2012. Consolidated Financial Results Improved in Third Quarter and First Nine Months". Planegg-Martinsried. 2012-11-08
4SC AG. (12/12/12). "Press Release: 4SC Announces Positive Interim Results from Clinical Phase I/II Trial with Anti-cancer Compound Resminostat in Colorectal Cancer". Planegg-Martinsried. 2012-12-12
4SC AG. (12/14/11). "Press Release: 4SC Forms Subsidiary to Commercialise Innovative Early-stage Drug Research Programmes and Strengthen Revenue from Research Collaborations". Planegg-Martinsried. 2011-12-14
4SC AG. (12/17/12). "Press Release: 4SC Discovery and BioNTech Announce Exclusive Research and License Agreement for 4SC’s TLR Agonists for Cancer Immunotherapy". Planegg-Martinsried & Mainz. 2012-12-17
4SC AG. (12/20/10). "Press Release: 4SC Completes Enrolment of the Phase IIb COMPONENT Trial with Vidofludimus in Rheumatoid Arthritis". Planegg-Martinsried. 2010-12-20
4SC AG. (12/22/10). "Press Release: 4SC Receives EU Grant to Identify New Drugs for the Treatment of Rheumatoid Arthritis as Part of a Consortium". Planegg-Martinsried. 2010-12-22
4SC AG. (12/7/11). "Press Release: 4SC Obtains Key Patent for Lead Anti-cancer Compound Resminostat in Japan". Planegg-Martinsried. 2011-12-07
4SC AG. (12/9/14). "Press Release: 4SC Reports Positive Topline Data from Clinical Phase I Trial with 4SC-205 in Cancer Patients Using Novel Continuous Dosing Scheme". Planegg-Martinsried. 2014-12-09
4SC AG. (2/1/18). "Press Release: Positive DSMB Safety Review of 4SC’s Pivotal RESMAIN Study of Resminostat in CTCL". Planegg-Martinsried. 2018-02-01
4SC AG. (2/10/15). "Press Release: 4SC's Associated Company Panoptes Pharma Concludes License Agreement with Mediolanum for Compound PP-001 for Inflammatory Eye Diseases". Planegg-Martinsried. 2015-02-10
4SC AG. (2/12/14). "Press Release: Continued Funding of 4SC AG. Investor Undertakes to Subscribe to Convertible Notes for up to EUR 15 Million Nominally [Ad hoc Announcement] ". Planegg-Martinsried. 2014-02-12
4SC AG. (2/20/13). "Press Release: 4SC Discovery and BioNTech Launch Strategic Cancer Therapy Research Partnership". Planegg-Martinsried & Mainz. 2013-02-20
4SC AG. (2/23/11). "Press Release: 4SC Announces Capital Increase". Planegg-Martinsried. 2011-02-23
4SC AG. (2/26/13). "Press Release: 4SC Discovery and Leo Pharma Announce Exclusive Research and License Agreement for Inflammatory Skin Diseases". Planegg-Martinsried & Ballerup. 2013-02-26
4SC AG. (2/6/17). "Press Release: 4SC AG to Present at the 19th Annual BIO CEO & Investor Conference 2017". Planegg-Martinsried. 2017-02-06
4SC AG. (3/1/12). "Press Release: 4SC Receives Patent Protection for Its Oncology Compound Resminostat in Taiwan and Three other Asian Growth Markets". Planegg-Martinsried. 2012-03-01
4SC AG. (3/12/13). "Press Release: Ad hoc. Notice of Loss Pursuant to Section 92 (1) German Stock Corporation Act (Aktiengesetz, AktG)". Planegg-Martinsried. 2013-03-12
4SC AG. (3/20/14). "Press Release: 4SC Discovery Collaborates with Heidelberg University Hospital and Receives EUR 1.3 Million for Research and Preclinical Development of New Malaria Drug". Planegg-Martinsried. 2014-03-20
4SC AG. (3/21/18). "Press Release: 4SC AG Announces Results for Financial Year 2017". Planegg-Martinsried. 2018-03-21
4SC AG. (3/24/16). "Press Release: Chairman of the Management Board Enno Spillner Will Not Extend His Current Term of Office, But Will Leave the Company After a Transitional Period Ending 30 June 2016". Planegg-Martinsried. 2016-03-24
4SC AG. (3/25/13). "Press Release: 4SC Announces Financial Results for a Successful Year 2012". Planegg-Martinsried. 2013-03-25
4SC AG. (3/25/15). "Press Release: 4SC Publishes Results for Financial Year 2014". Planegg-Martinsried. 2015-03-25
4SC AG. (3/26/14). "Press Release: 4SC Publishes Results for Financial Year 2013 and Announces Changes to the Management Board". Planegg-Martinsried. 2014-03-26
4SC AG. (3/27/18). "Press Release: Yakult Honsha Joins 4SC’s Pivotal RESMAIN Study of Resminostat in CTCL – 4SC Receives Milestone Payment". Planegg-Martinsried. 2018-03-27
4SC AG. (3/29/12). "Press Release: 4SC Announces Financial Results 2011". Planegg-Martinsried. 2012-03-29
4SC AG. (3/30/16). "Press Release: 4SC Announces Results for Financial Year 2015". Planegg-Martinsried. 2016-03-30
4SC AG. (3/4/14). "Press Release: 4SC AG Issues First Tranche of Convertible Notes with a Nominal amount of EUR 500,000 to Yorkville". Planegg-Martinsried. 2014-03-04
4SC AG. (3/6/13). "Press Release: 4SC AG. Dr Ulrich Dauer to Step Down as CEO and Member of the Management Board on 31 March 2013, His Successor Will Be CFO Enno Spillner". Planegg-Martinsried. 2013-03-06
4SC AG. (4/1/15). "Press Release: Dr Susanne Danhauser-Riedl Joins 4SC as Chief Medical Officer to Strengthen Management and Clinical Development Team". Planegg-Martinsried. 2015-04-01
4SC AG. (4/11/18). "Press Release: Yakult Honsha Recruits First Japanese Patient in 4SC’s Pivotal RESMAIN Study of Resminostat in CTCL". Planegg-Martinsried. 2018-04-11
4SC AG. (4/14/11). "Press Release: 4SC and Yakult Hinsha Announce Exclusive License Agreement for Japan for the Oral HDAC Inhibitor Resminostat". Planegg-Martinsried & Tokyo. 2011-04-14
4SC AG. (4/14/15). "Press Release: 4SC Signs Licensing and Development Agreement with Menarini for Resminostat in Asia-Pacific Excluding Japan". Planegg-Martinsried & Singapore. 2015-04-14
4SC AG. (4/15/14). "Press Release: 4SC Discovery Receives EU Grant Worth EUR 450,000 for the Research of New Epigenetic Compounds against Stroke". Planegg-Martinsried. 2014-04-15
4SC AG. (4/17/18). "Press Release: 4SC at AACR – Broadened Clinical Options for 4SC-202". Planegg-Martinsried. 2018-04-17
4SC AG. (4/18/12). "Press Release: 4SC Discovery and Crelux Enter into a Strategic Alliance for Joint Drug Discovery Services". Planegg-Martinsried. 2012-04-18
4SC AG. (4/19/18). "Press Release: Phase II Study of 4SC’s Resminostat in Biliary Tract Cancer in Japan Is Initiated". Planegg-Martinsried. 2018-04-19
4SC AG. (4/2/12). "Press Release: Henkel and 4SC Discovery Start Research Collaboration in Compound Screening". Planegg-Martinsried. 2012-04-02
4SC AG. (4/29/16). "Press Release: 4SC Sells Operations of Its Discovery Division [Ad hoc announcement according to $ 15 WpHG]". Planegg-Martinsried. 2016-04-29
4SC AG. (4/30/12). "Press Release: 4SC Receives Milestone Payment from Research Collaboration with SKK". Planegg-Martinsried. 2012-04-30
4SC AG. (5/10/11). "Press Release: 4SC Announces Financial Results for the First Quarter 2011". Planegg-Martinsried. 2011-05-10
4SC AG. (5/14/13). "Press Release: 4SC Significantly Improves Operating Result in First Quarter of 2013 and Resolves to Focus Its Development Strategy". Planegg-Martinsried. 2013-05-14
4SC AG. (5/27/16). "Press Release: 4SC Provides Headline Results from Yakult Honsha’s Phase II Trial of Resminostat in Combination with Sorafenib as First Line Therapy in Liver Cancer (Ad hoc announcement according to § 15 WpHG)". Planegg-Martinsried. 2016-05-27
4SC AG. (5/30/13). "Press Release: 4SC Gives Update on the Clinical Development of Its Lead Cancer Compound Resminostat". Planegg-Martinsried. 2013-05-30
4SC AG. (5/31/16). "Press Release: 4SC Enters into Licensing and Development Partnership with Link Health for the Cancer Compound 4SC-205 in China". Planegg-Martinsried. 2016-05-31
4SC AG. (5/8/14). "Press Release: 4SC Announces Financial Results for the First Quarter of 2014". Planegg-Martinsried. 2014-05-08
1 2 3 ... 167 168 169  next pagenext page



Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco Investors 600x60px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco Investors 600x60px

» top